Patients with primary malignant brain tumors manifest a variety of abnormalities in cell-mediated and humoral immunity. Diminished T cell reactivity has been shown in these patients to be linked to deficiencies in interleukin 2 (IL-2) production that cannot be overcome by exogenous IL-2. In this study, specific binding of radiolabeled IL-2 to PHA-stimulated lymphocytes from brain tumor patients demonstrates that the number of high affinity interleukin 2 receptors (IL-2R) is greatly reduced. FACS analysis indicates that the relative density of the p55 protein (Tac protein) is lower on the mitogen-activated lymphocytes obtained from patients than on comparably treated lymphocytes from normal individuals. These data indicate that mitogen-stimulated lymphocytes obtained from patients have fewer functional high affinity IL-2R principally because of the failure to express sufficient levels of the p55 protein for association with the p75 protein. Northern analysis of total RNA isolated from mitogen-stimulated T cells from patients demonstrates normal levels of steady state mRNA, which codes for the p55 protein. Moreover, there is no defect in the postranslational processing of the primary translation product of this mRNA suggesting that normal levels of the p55 protein are produced in activated T cells from patients. (J. Clin. Invest. 1990. 86:80-86.)
Introduction
Patients with primary malignant intracranial neoplasms exhibit broad suppression of immunocompetency as manifest through a variety of in vivo and in vitro determinants (1) (2) (3) (4) (5) (6) (7) (8) (9) . Most notably, the T cell hyporesponsiveness observed in these patients is a result of the failure of these cells to enter and complete the proliferative cycle when compared to comparably stimulated T cells obtained from normal individuals (10) . This functional defect of the T cell cannot be attributed to an inability to bind lectin, enhanced suppressor cell activity (1 1), or anomalous accessory cell function and secretion of interleukin 1, which are required for stimulation (10) . However, T cells obtained from these patients do not secrete normal chain (p55, or Tac protein) and a 75-kD polypeptide chain (p75) linked by noncovalent interactions (13) (14) (15) (16) (17) (18) . Although lymphocyte proliferation can be induced without mitogen via interaction of IL-2 with p75 (19) , the formation of the high affinity IL-2R is more efficient because the concentration of IL-2 required to induce proliferation is significantly less in lymphocytes expressing high affinity IL-2R than in those T cells expressing the p75 only. As a corollary, failure to assemble and express the high affinity IL-2R would result in diminished lymphocyte proliferation under physiological conditions. Investigating this possibility as an explanation for diminished T cell proliferation observed in patients with malignant gliomas, we now report that lymphocytes obtained from these patients express normal levels ofthe p75. However, the high affinity IL-2R as well as p55 are significantly lower than normal after lectin stimulation.
Methods
Patient population. All patients received diagnosis of either glioblastoma multiforme or anaplastic astrocytoma with signs of progressive tumor growth. None received radiation, systemic steroids, or phenytoin at the time ofthe study. Both men and women ranged in age from 18 to 68 yr (median, 42 yr). Healthy hospital employees, ranging in age from 24 to 56 years (median, 30 yr) served as normal controls.
Lymphocyte preparation and culture. Peripheral blood lymphocytes (PBL) were isolated by centrifugation at 400 g for 35 min on a Ficoll-Hypaque gradient (20 After centrifugation to remove the nuclei, the lysates were precleared with washed Staphylococcus aureus (Pansorbin; Calbiochem-Behring, San Diego, CA) and incubated overnight at 4VC with 10 gg/ml of anti-Tac MAb. An irrelevant MAb (anti-coronavirus; Chemicon, El Segundo, CA) of the same class (IgG2a) was added to control tubes. The lysates were reacted with the antibodies overnight at 4VC, then 50 ,Ml of washed Pansorbin was added, and the tubes were incubated at 4VC for 60 min with rotation. The antibody-Pansorbin complexes were collected by centrifugation at 13,000 g for 5 min and the pellet was washed successively in 1 ml wash buffer-l (lysis buffer plus 0.5 M NaCI), wash buffer-2 (lysis buffer plus 0.1% SDS) and wash buffer-3 (10 mM Tris-HCl buffer pH 7.4, 0.1% NP-40). The pellets were resuspended in 50 Ml of SDS sample buffer (5 mM Tris-HCl buffer pH 6.8, 0.4% SDS, 2% glycerol, 1% 2-mercaptoethanol, 0.01% bromophenol blue) boiled for 5 min and centrifuged 13,000 g for 4 min. The supernatants were analyzed by electrophoresis on a 10% SDS-polyacrylamide gel.
Results
Determination of the number of high affinity IL-2R on PHAactivated T cells obtainedfrom patients with brain tumors. We have previously reported that PHA-activated lymphocytes obtained from patients with glioblastomas contain significantly lower than normal numbers of IL-2 receptor-positive cells, as measured by indirect immunofluorescent staining with antiTac MAb (12) . Since the anti-Tac MAb binds to both the functional high affinity IL-2R and the nonfunctional low affinity p55 IL-2R, it was of interest to determine which of these receptors was being affected. Binding assays were initiated using radiolabeled IL-2 to determine the affinity and number of IL-2R expressed on PHA-activated T cells from patients with brain tumors. The comparative results of Scatchard analysis of '251I-I-L2 binding to lymphocytes from a patient with a brain tumor and a normal subject illustrate that although T cells obtained from patients express high-affinity IL-2R, the levels of these receptors are significantly less (threefold) than those found on lymphocytes obtained from normal individuals (Fig. 1) . Indeed, high affinity IL-2R were completely un- detectable on mitogen-stimulated T cells collected from four of seven patients (Table I) . Expression ofthe p55 and p75 IL-2R on PHA-activated T lymphocytes obtainedfrom patients with brain tumors. Recent evidence reveals that the functional high affinity IL-2R is assembled by noncovalent interaction between the p55 IL-2R and the p75 IL-2R (13) (14) (15) (16) (17) . The p55 IL-2R binds IL-2 with low affinity while the p75 IL-2R binds with intermediate affinity. Therefore, the possibility exists that an absence ofeither the p55 or p75 chains of the IL-2R or failure of their association in the assembly of the high-affinity IL-2R could be responsible for the diminished expression of high-affinity IL-2R on mitogen-stimulated T cells obtained from brain tumor patients. Scatchard analysis (Fig. 2 ) of 125I-IL-2 binding to activated T cells from a patient illustrates that although these cells fail to express normal levels of the high affinity IL-2R (591 sites/cell, Kd 8.3 pM) they do express sufficient levels (1,833 sites/cell) of the p75 IL-2R that bind IL-2 with intermediate affinity (Kd 83 pM) . In fact, Scatchard analysis ofthe data from binding assays using lymphocytes from three different patients indicate that the number of p75 IL-2R are present in excess (greater than threefold) of the high affinity IL-2 binding sites. Thus, the p75 is readily expressed on activated T cells obtained from glioma patients and is available for IL-2 binding. However the relative density ofp55, as determined by flow cytometry using anti-Tac MAb, is significantly lower on activated T cells from patients when compared with similarly treated cells from normal individuals (Fig. 3) . II) suggest that although there is variability among both populations of cells, the T cells obtained from patients and normals appear to express similar steady state levels of mRNA for p55. Moreover, there does not appear to be any significant differences in the ratio ofthe two major mRNA species (3.5/1.5 kb).
Posttranslational processing of the p55 gene product. Because there does not appear to be a defect in the transcription of the gene for p55, it was of interest to determine if the decreased expression of this protein on the surface of activated T cells from patients was the result of a defect in the posttranslational modification ofp55. The primary translation product of the p55 mRNA is a 34-kD peptide (p34) (24) . Cleavage of a signal peptide results in the formation of a 33-kD peptide that is evident at early time points. Cotranslational addition of NH2-linked oligosaccharides yields two more precursor peptides p35 and p37. The p35/p37 precursors are further pro- cessed in the Golgi through p37 to the mature p55 by the addition of 0-linked carbohydrates and sialic acid (24).
[35S]Methionine pulse-chase experiments were performed on PHA-activated T cells from normal individuals and brain tumor patients to determine if there were any difference in the posttranslational processing of p55, which might account for its decreased expression on the cell surface. Radiolabeled proteins were specifically immunoprecipitated with anti-Tac MAb and analyzed by SDS-PAGE (Fig. 5) . After 0 and 15 min determine the number and affinity ofIL-2R on PHA-activated T cells obtained from brain tumor patients. The results demonstrate that expression of high affinity IL-2R is suppressed on these cells when compared to PHA-activated T cells obtained from normal individuals. Therefore, an attractive explanation for the impaired lymphocyte reactivity of these patients is the failure of stimulated T cells to express sufficient levels of the high affinity IL-2R required for proliferation. The high affinity IL-2 receptor is a complex structure consisting of at least two noncovalently linked polypeptide chains (p55 and p75), both of which have binding sites for IL-2 (13) (14) (15) (16) (17) . Although, recent evidence indicates that the p75 IL-2R is the biologically relevant moiety for transduction of the IL-2 signal, the induced expression of the p55 after lymphocyte stimulation is important in augmenting IL-2 binding via the newly assembled high affinity IL-2R (19, 25, 26) . Normally, p55 is expressed on activated T cells in excess (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) fold) of the p75 (26) . It has been hypothesized that one function of the p55 is to insure that the p75 is always occupied in the formation ofthe functional high affinity IL-2R (26) . In our studies, the relative density of the p55 as measured by flow cytometry using anti-TAC MAb is significantly less on activated T cells from patients with brain tumors when compared to similarly treated cells from normal individuals. Moreover, the intermediate affinity p75 IL-2R is always expressed in excess (greater than threefold) of the high affinity IL-2R on activated lymphocytes obtained from patients with brain tumors. Collectively, these data suggest that mitogen-stimulated T cells obtained from patients with malignant gliomas express lower levels of the functional high affinity IL-2R principally because they have insufficient levels of p55 available for association with p75.
The explanation for diminished p55 expression after lectin stimulation remains to be elucidated. It is evident, however, that altered T cell responsiveness of patients with gliomas is linked to abnormal IL-2R formation and expression. However, the earliest events of mitogen-induced lymphocyte activation required for the development of competency to begin the proliferative cycle, e.g., lectin binding, phosphoinositide hydrolysis and protein kinase C translocation, occur normally in T cells obtained from brain tumor patients (unpublished observations). It may be hypothesized that the failure to express p55 and hence inability to assemble high-affinity IL-2R required for proliferation stems from defects in regulation of IL-2R gene transcription and/or translation. However, Northern blot analysis of total RNA extracted from activated T cells obtained from patients with brain tumors indicates that these cells express normal steady-state levels of mRNA for p55.
Leonard et al. (27) have noted a predominance of the 3.5-kb species in cells that express low levels of IL-2R. They suggest that, although both species code for protein, the 1.5-kb species may be the one that varies with the magnitude of IL-2R expression. This does not appear to be the case in our system. The ratio of 3.5/1.5 mRNA is similar for cells obtained from patients and normal individuals.
The primary translation product of the mRNA for p55 is a peptide with a molecular weight of 34 kD (p34), which undergoes extensive post-translational modification to yield the final protein product of 55 kD (24) . All the precursor peptides except p34 bind IL-2, thus, these extensive posttranslation modifications do not appear to be essential to ligand binding. However, these modifications may alter the affinity with which the p55 IL-2R binds IL-2 (24) . The data presented in this study with PHA-activated T cells obtained from patients indicate that mRNA for p55 is translated into a product which undergoes normal post-translational processing resulting in synthesis of normal levels of mature p55 protein. Thus, it appears that the failure of activated T cells from brain tumor patients to assemble functional high affinity IL-2R can not be attributed to defects in transcription ofthe gene or translation ofthe mRNA that code for p55.
These data do not correlate with the observed decreased expression of the Tac protein on activated T cells from patients. There are a number of possible explanations that may account for these discrepancies. First, p55 may be degraded in lymphocytes from brain tumor patients before it is expressed on the cell surface. Second, there is evidence (28, 29) that T cell lines, as well as mitogen-activated lymphocytes from normal individuals, which express mature p55 on their cell surface also release measurable levels of this protein into the culture supernatant. The secreted form demonstrates an apparent molecular mass of 45-50 kD, which is smaller than the p55 surface receptor on these cells. Thus, the release of soluble p55 IL-2R appears to be a characteristic of T cell activation and may play an immunoregulatory role in lymphocyte activation (28) . It may be hypothesized that this normal process of p55 IL-2R secretion has been upregulated in activated lymphocytes from patients, thus reducing the levels of this protein on the cell surface. Finally, the glioma may be secreting factors, which, in some unknown manner mask or prevent the expression of p55 on the cell surface and prevent assembly of the functional high affinity IL-2R. Experiments are in progress to test these possibilities.
The results of the present study provide insights into the potential therapeutic role of lymphokine-activated killer cells (LAK-cell), cytotoxic T lymphocytes (CTL) and/or IL-2 infusion, as well as into the immunobiologic relationship between glioma cells -and lymphocytes. In vitro, high doses of IL-2 promote the growth and expansion of LAK cells obtained from these patients yet the numbers are greatly reduced when compared with healthy controls (30) (31) (32) . Glioma specific CTL also may be isolated from tumor tissue but are exceedingly low in their proliferative response to IL-2 (32-34). Moreover, tumor infiltrating lymphocytes that are positive for a variety of T cell markers do not express the p55 IL-2R (33) . Hence the inability of lymphocytes obtained from these patients to express functional high-affinity IL-2R offers one explantation for the limited inducible expansion of these IL-2-dependent lymphocyte subpopulations as well as the relative ineffectiveness of LAK cells and/or IL-2 in treating patients with malignant gliomas (35, 36) .
The relationship between the presence of a malignant brain tumor and alterations in intrinsic lymphocyte function as demonstrated in this and previous investigations remains conjectural. Previously, we (37) and others (38) (39) (40) have demonstrated that glioma cells secrete a factor(s) capable of modulating lymphocyte proliferative responsiveness. These factors suppress the responsiveness of T cells obtained from both patients with brain tumors as well as normal individuals. Recent evidence indicates that glioma suppressor factor(s) impair reactivity of T cells obtained from healthy individuals by modulation of the expression of the high affinity IL-2R (unpublished observation); a finding similar to that observed in T cells obtained from patients with gliomas. How this abrogation of IL-2R assembly and/or expression is affected is conjectural. Nonetheless, it is tempting to postulate that broad suppression of immune responsiveness in glioma patients results from an interaction between glioma suppressive factor and circulating T cells, which modifies the ability these cells to express the functional high affinity IL-2R.
